
Biocryst sells Europe business; Peter Marks criticizes new FDA vaccine rules
Today, a brief rundown of news involving Biocryst and Peter Marks, as well as updates from UCB and Altimmune that you may have missed. Biocryst said Friday it is selling the European business of its hereditary angioedema drug Orladeyo to Italy’s Neopharmed …